Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-...
Guardado en:
Autores principales: | Caterina Cinti, Monia Taranta, Ilaria Naldi, Settimio Grimaldi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/81c931ba19404e169be4fe92b6191047 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line.
por: Enrico Capobianco, et al.
Publicado: (2014) -
A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries
por: Aman P. Mann, et al.
Publicado: (2016) -
Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
por: Kim JS, et al.
Publicado: (2018) -
Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery
por: Chen X, et al.
Publicado: (2012) -
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
por: Xuqing Zhang, et al.
Publicado: (2021)